Ibrutinib, Free Base

Ibrutinib, Free Base
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LC-I-3311_10mg 10 mg -

3 - 15 business days*

74.00€
LC-I-3311_25mg 25 mg -

3 - 15 business days*

86.00€
LC-I-3311_50mg 50 mg -

3 - 15 business days*

106.00€
LC-I-3311_100mg 100 mg -

3 - 15 business days*

134.00€
LC-I-3311_200mg 200 mg -

3 - 15 business days*

169.00€
LC-I-3311_500mg 500 mg -

3 - 15 business days*

292.00€
LC-I-3311_1g 1 g -

3 - 15 business days*

412.00€
LC-I-3311_2g 2 g -

3 - 15 business days*

646.00€
LC-I-3311_5g 5 g -

3 - 15 business days*

1,273.00€
 
Solubility: Soluble in DMSO at 200 mg/mL, soluble in ethanol at 25 mg/mL with slight warming.... more
Product information "Ibrutinib, Free Base"
Solubility: Soluble in DMSO at 200 mg/mL, soluble in ethanol at 25 mg/mL with slight warming. Ibrutinib, also known as PCI-32765, is a selective and irreversible inhibitor of the enzyme Bruton's tyrosine kinase (BTK). It inhibited BTK potently, with an IC50 of 0.72 nM in enzymology assays and with an IC50 of 10 nM in cellular assay with Ramos cells. It demonstrated preference toward BTK over closely related kinases, blocked B cell function and BTK-dependent processes, and demonstrated clear efficacy in a mouse arthritis model. Young P.R., et al. 'Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.' ChemMedChem. 2: 58-61 (2007). Ibrutinib blocked B-cell antigen receptor (BCR) signaling in human peripheral B cells at concentrations which did not change T cell receptor signaling, reduced the level of circulating autoantibodies and completely suppressed collagen-induced arthritis in mice, inhibited the production of autoantibodies and the development of kidney disease in the MRL-Fas(lpr) lupus model, and induced objective clinical responses in dogs with spontaneous B-cell non-Hodgkin lymphoma. Active site occupancy of BTK was closely correlated with the inhibition of BCR signaling and in vivo efficacy. Honigberg L.A., et al. 'The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.' Proc. Natl. Acad. Sci. USA 107: 13075-13080 (2010). Ibrutinib was well tolerated and had significant activity in patients with relapsed/refractory B-cell malignancies. Advani R.H., et al. 'Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.' J. Clin. Oncol. 31: 88-94 (2013).
Keywords: CRA-032765, PCI-32765, PCI-32765-00
Supplier: LC Laboratories
Supplier-Nr: I-3311

Properties

Application: Selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor
MW: 440.5 D
Formula: C25H24N6O2
Purity: >99%
Format: Solid

Database Information

CAS : 936563-96-1| Find alternatives
KEGG ID : K07370 | Find alternatives

Handling & Safety

Storage: -20°C
Shipping: +20°C (International: °C)
Signal Word: Warning
GHS Hazard Pictograms:
H Phrases: H302+H312+H332
P Phrases: P262
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Ibrutinib, Free Base"
Write a review
or to review a product.
Ibrutinib Ibrutinib
From 37.00€ *
Ibrutinib Ibrutinib
From 139.00€ *
PCI-32765 PCI-32765
From 75.00€ *
Ibrutinib Ibrutinib
From 88.00€ *
Viewed